Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
faecal microbiota transplantation (University Hospital of North Norway)
- Development stage
- Unknown
- Lead developer
- Universitetssykehuset Nord-Norge
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Faecal microbiota transplantation (FMT) is an investigational microbial therapy being evaluated by the University Hospital of North Norway for its potential to treat Alzheimer's disease. The procedure involves the administration of a preprocessed, thawed donor fecal suspension into the patient's colon via colonoscopy. This approach targets the gut-brain axis, aiming to restore a healthy microbial balance and mitigate the neuroinflammatory processes linked to the progression of Alzheimer's disease. Currently, it is being assessed in a Phase 1 clinical trial to determine its safety and feasibility in patients with mild to moderate cognitive impairment.
- Other names
- FMTfecal microbiota transplantation
Beyond the preview
Go deeper on faecal microbiota transplantation (University Hospital of North Norway).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on faecal microbiota transplantation (University Hospital of North Norway).